Close Menu

You may find more results for this query on our sister sites: 360Dx and Precision Oncology News.

Home » Business, Policy & Funding » With BlueGnome Buy, Illumina Expands Presence in Cyto Market, Moves into IVF Testing

With BlueGnome Buy, Illumina Expands Presence in Cyto Market, Moves into IVF Testing

Sep 25, 2012
|
Justin Petrone
Premium

This article has been updated from a version posted Sept. 19 to include comments from Illumina officials.

Illumina's acquisition of BlueGnome, announced last week, will broaden the San Diego firm's opportunities in molecular diagnostics, according to its top executive.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

GenomeWeb Premium gives you:
✔ Full site access
✔ Interest-based email alerts
✔ Access to archives

Never miss another important industry story.

Try GenomeWeb Premium now.

You may already have institutional access!

Check if I qualify.

Already a GenomeWeb or 360Dx Premium member?
Login Now.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

The Scan

Breathe It Out

Researchers are developing a breath test to determine how severe patients' methylmalonic acidemia disease is, FierceBiotech reports.

The Next Batch

NPR reports that vaccine developers are working on SARS-CoV-2 vaccines that are easier to store or administer than the current crop.

Switch for the Second

Reuters reports that France is to recommend that people under 55 who received one dose of AstraZeneca's SARS-CoV-2 vaccine receive a different vaccine for their second dose.

Science Reviews How Non-Genetic DNA Features Expand Utility of Liquid Biopsies, Presents Study of Enzymes in DNA Methylation

In Science this week: review discusses advances in liquid biopsies, and more.

May
05
Featured Webinar

Establishing a Pharmacogenomic Service for Routine Clinical Care

Sponsored by
Illumina

Adverse drug reactions (ADRs) are responsible for around 5 percent of hospital admissions and occur in 6 percent to 15 percent of hospital stays.

What's Popular?

In Microarrays & Multiplexing

  1. GWAS Uncovers Sex-Based Differences in Genetic Origins of Chronic Pain

Sponsorships

Privacy Policy.  Terms & Conditions.  .  Copyright © 2021 GenomeWeb, a business unit of Crain Communications.  All Rights Reserved.